VolitionRx Earnings Call Transcripts
Fiscal Year 2025
-
Achieved strong revenue growth and major clinical/commercial milestones in 2025, including first clinical orders for Nu.Q Cancer and NETs, automation breakthroughs in vet diagnostics, and validation of Capture-Seq technology. Focus shifted to commercialization with ongoing cost reductions and multiple licensing deals expected in 2026.
-
Q3 revenue rose 32% year-over-year with significant cost reductions and narrowed net loss. Major agreements with Werfen and Hologic are expected to drive future growth, while new technologies and automation expand both human and veterinary diagnostics.
-
Nu.Q assays enable sensitive, quantitative detection of histone modifications in circulating nucleosomes, supporting cancer diagnosis, prognosis, and pharmacodynamic monitoring of epigenetic therapies. They complement ctDNA and protein markers, aid early toxicity detection, and are customizable for diverse research needs.
-
Q2 saw a 9% drop in operating expenses and a 15% rise in H1 revenue, with first human product sales and strong licensing progress. Advanced negotiations with major partners and robust clinical results position the company for imminent out-licensing deals and global expansion.
-
Revenue grew 44% year-over-year, driven by the first human product sales and strong cost controls, with operating expenses down 35%. Multiple licensing discussions and clinical milestones position the company for further growth, while a $6.25M convertible loan note strengthens liquidity.
Fiscal Year 2024
-
Revenue grew 59% in 2024, driven by Nu.Q Vet and Discover, while operating expenses fell 23%. Major clinical milestones and global expansion were achieved, with 2025 focused on licensing deals and automation to drive further growth.
-
Q3 2024 saw record Nu.Q Vet Cancer Test sales, 100%+ revenue growth, and major cost reductions. Strong progress in human diagnostics and licensing discussions positions the company for cash neutrality in 2025, with further expansion and deals expected.
-
H3.1 nucleosome testing shows strong, consistent predictive value for sepsis severity and organ failure, with rapid, easy-to-use technology validated across large European cohorts. Commercialization efforts are advancing, targeting a multi-billion dollar market with active licensing discussions and regulatory preparations underway.
-
Record Nu.Q Vet Cancer Test sales and global launches drove 83% revenue growth in Q2 2024, while cost-cutting and new funding support the goal of cash flow positivity in 2025. Major clinical milestones and licensing deals in human health are targeted for H2 2024.